

PRESS RELEASE

Alfonso Camba appointed VP Manufacturing Operations of Cellerix

Madrid, 11th November, 2008.- Cellerix, a biopharmaceutical company that develops and produces innovative treatments based on cell therapy, has appointed Alfonso Camba as VP Manufacturing Operations.

Mr Camba holds a degree in Pharmacy from the *Universidad Complutense de Madrid*, where he specialised in Biochemistry, and an Executive MBA master's degree from *Instituto de Empresa*. Mr Camba has held different positions in companies such as Merck Sharp and Dohme, Bioter, Sterling Withrop and Serono during his thirty years of experience in the pharmaceutical and biotechnological sector, both in Spain and abroad.

Eduardo Bravo, Cellarix' CEO, highlighted the importance of having a professional with the background of Alfonso Camba on the company's Executive Committee. *"With, Ontaril[®] and Cx501 getting closer to the market, having someone with Alfonso's experience in production and logistics will be of great added value for our company"*, Bravo said.

Prior to joining Cellarix, Alfonso Camba worked with Serono in different positions, including as Operations Director in Spain, as Operations Deputy Chairman in Boston and as Corporate Deputy Chairman and member of the Strategic Committee in Geneva. In 2003, Mr Camba joined Filaxis Argentina as Chairman and main shareholder. He also has worked as adviser and member of the Science and Investments Committee of Suanfarma.

ABOUT CELLERIX

Cellerix is a product-focused biopharmaceutical company developing innovative medicines based on cell therapy. The company has two products undergoing clinical trials: Ontaril[®] for the treatment of perianal fistulas, which has ended the recruitment for the first trial in Phase III, and Cx501 for skin regeneration, currently in Phase II. Ontaril[®] and Cx501 have orphan status by the European Medicines Agency (EMA). Cellarix closed in September 2007 a €27.2 million financing round led by international venture capital companies. In October 2007 it entered into an exclusive license and development agreement with Axcan Pharma for the North American rights to Ontaril[®]. In September this year Cellarix obtained a 10M€ debt facility with venture capital firm ETV Capital.